Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Por um escritor misterioso
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
Treatment National Cancer Institute
MEN1 mutations mediate clinical resistance to menin inhibition
Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Biomedicines, Free Full-Text
Revumenib Shows Promise in Acute Leukemia - CancerConnect
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant
I-131 apamistamab induces response among adults with advanced
Clinical Trial Results - Cancer Currents Blog - NCI
Revumenib: a new therapy for AML patients
de
por adulto (o preço varia de acordo com o tamanho do grupo)
